Deligiannidis KM, Meltzer-Brody S, Gunduz-Bruce H, et al. - FIndings from this phase 3, double-blind, randomized, outpatient, placebo-controlled clinical trial suggest zuranolone, a neuroactive steroid γ-aminobutyric acid receptor–positive allosteric modulator, as efficacious and safe in treating postpartum depression (PPD).

• Participants were women with PPD (major depressive episode beginning third trimester or ≤ 4 weeks post delivery).

• The women were randomized to receive placebo or zuranolone, 30 mg, orally each evening for 2 weeks.

• Greater statistically significant reductions in depressive symptoms were recorded in patients taking daily zuranolone vs placebo at day 15, as assessed by change from baseline in the 17-item Hamilton Rating Scale for Depression.

• There were decreases in depressive symptoms by day 3, that remained sustained at all measured time points through day 45.